Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

J.M. Del Campo,A Roszak,M. Bidzinski,T. Ciuleanu,Thomas Högberg,M Z Wojtukiewicz,A. Poveda,Karin Boman,A. M. Westermann,C. Lebedinsky

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

2009

J.M. Del Campo
A Roszak
M. Bidzinski
T. Ciuleanu
Thomas Högberg
M Z Wojtukiewicz
A. Poveda
Karin Boman
A. M. Westermann
C. Lebedinsky

BACKGROUND: This randomized, open-label, phase II clinical trial evaluated the optimal regimen of trabectedin administered every 3 weeks in patients with platinum-sensitive, relapsed, advanced ovar ...

Keywords:

Ovarian cancer
Randomized controlled trial
Pathology
Trabectedin
Regimen
Medicine
Chemotherapy regimen
Phases of clinical research
Neutropenia
Nausea
Intention-to-treat analysis
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations